Cancer Research UK logo.
SearchDonate
  • Search

A study of IMM-101 and nivolumab for people with advanced melanoma

Overview

Cancer types:

Melanoma, Secondary cancers, Skin cancer

Status:

Closed

Phase:

Phase 2

Details

This study is looking at adding IMM-101 to nivolumab for melanoma that has grown into surrounding tissues or spread elsewhere in the body. This is called advanced melanoma.

Recruitment start: 4 October 2018

Recruitment end: 1 June 2020

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Alberto Fusi

Supported by

Immodulon Therapeutics Limited

Last reviewed: 29 Jun 2021

CRUK internal database number: 15720

Help and support